Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV type 1 infection.
about
Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.CD4+ T cell-dependent and CD4+ T cell-independent cytokine-chemokine network changes in the immune responses of HIV-infected individualsSecond European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, SpainReview article: the intersection of mucosal pathophysiology in HIV and inflammatory bowel disease, and its implications for therapy.Innate immunity against HIV-1 infection.Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.Sex-Related Differences in Inflammatory and Immune Activation Markers Before and After Combined Antiretroviral Therapy Initiation.The HIV-1 Vpr Protein: A Multifaceted Target for Therapeutic Intervention.Evaluation of HIV-DNA and inflammatory markers in HIV-infected individuals with different viral load patterns.The APPEESFRS Peptide, Restricted by the HLA-B*35:01 Molecule, and the APPEESFRF Variant Derived from an Autologous HIV-1 Strain Induces Polyfunctional Responses in CD8+ T Cells.Peripheral TNFα elevations in abstinent alcoholics are associated with hepatitis C infection.High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control.Hydroxypropyl-Beta-Cyclodextrin Reduces Inflammatory Signaling from Monocytes: Possible Implications for Suppression of HIV Chronic Immune Activation
P2860
Q35567828-01C40B48-2E60-4C66-9E9B-8FD041E773C4Q36253312-A6B7CA5B-D95B-4778-A700-31326311F864Q37098390-9EEE9467-0C38-4379-BBDE-54628D922E4FQ38255412-01364F51-E131-4BAF-BF1E-D78D7392058BQ38491184-78723ADD-7E69-4FCC-8EF8-8FCA2E5E441CQ38832958-0755C909-2D48-4D2D-B5BF-53F3DBFC6C01Q38858603-72C987FB-F170-4D94-82A6-E61AC4E2723EQ39079514-1C7E23E4-209C-4907-9D45-33292F3BF817Q40075058-0356A03D-26C4-4531-9336-94AA3A70BF07Q41169502-9FA032D6-8E81-40BD-94DC-EC44A2BEBF35Q48097218-C56220F8-15C6-4D7F-BD06-6B21C0EB593CQ55400910-605FCDE5-FF6C-4A16-AA3E-025C4ED071A7Q58599380-F87646CF-923D-47CE-9DF8-3BBDAACD5200
P2860
Tumor necrosis factor α is associated with viral control and early disease progression in patients with HIV type 1 infection.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@ast
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@en
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@nl
type
label
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@ast
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@en
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@nl
prefLabel
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@ast
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@en
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@nl
P2093
P2860
P356
P1476
Tumor necrosis factor α is ass ...... nts with HIV type 1 infection.
@en
P2093
Eric S Rosenberg
Jenna Rychert
Michael N Sirignano
Molly Amero
Ronald J Bosch
Sagar A Vaidya
Sue Bazner
Todd M Allen
P2860
P304
P356
10.1093/INFDIS/JIU206
P407
P577
2014-03-31T00:00:00Z